Literature DB >> 27013733

HIV-1 broadly neutralizing antibody precursor B cells revealed by germline-targeting immunogen.

Joseph G Jardine1, Daniel W Kulp1, Colin Havenar-Daughton2, Anita Sarkar3, Bryan Briney1, Devin Sok1, Fabian Sesterhenn4, June Ereño-Orbea5, Oleksandr Kalyuzhniy1, Isaiah Deresa2, Xiaozhen Hu6, Skye Spencer6, Meaghan Jones6, Erik Georgeson6, Yumiko Adachi1, Michael Kubitz1, Allan C deCamp7, Jean-Philippe Julien8, Ian A Wilson9, Dennis R Burton10, Shane Crotty11, William R Schief12.   

Abstract

Induction of broadly neutralizing antibodies (bnAbs) is a major HIV vaccine goal. Germline-targeting immunogens aim to initiate bnAb induction by activating bnAb germline precursor B cells. Critical unmet challenges are to determine whether bnAb precursor naïve B cells bind germline-targeting immunogens and occur at sufficient frequency in humans for reliable vaccine responses. Using deep mutational scanning and multitarget optimization, we developed a germline-targeting immunogen (eOD-GT8) for diverse VRC01-class bnAbs. We then used the immunogen to isolate VRC01-class precursor naïve B cells from HIV-uninfected donors. Frequencies of true VRC01-class precursors, their structures, and their eOD-GT8 affinities support this immunogen as a candidate human vaccine prime. These methods could be applied to germline targeting for other classes of HIV bnAbs and for Abs to other pathogens.
Copyright © 2016, American Association for the Advancement of Science.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27013733      PMCID: PMC4872700          DOI: 10.1126/science.aad9195

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  34 in total

1.  Reference values for B cell subpopulations from infancy to adulthood.

Authors:  H Morbach; E M Eichhorn; J G Liese; H J Girschick
Journal:  Clin Exp Immunol       Date:  2010-09-20       Impact factor: 4.330

2.  Generation of stable monoclonal antibody-producing B cell receptor-positive human memory B cells by genetic programming.

Authors:  Mark J Kwakkenbos; Sean A Diehl; Etsuko Yasuda; Arjen Q Bakker; Caroline M M van Geelen; Michaël V Lukens; Grada M van Bleek; Myra N Widjojoatmodjo; Willy M J M Bogers; Henrik Mei; Andreas Radbruch; Ferenc A Scheeren; Hergen Spits; Tim Beaumont
Journal:  Nat Med       Date:  2009-12-20       Impact factor: 53.440

3.  HIV-1 neutralizing antibodies display dual recognition of the primary and coreceptor binding sites and preferential binding to fully cleaved envelope glycoproteins.

Authors:  Yuxing Li; Sijy O'Dell; Richard Wilson; Xueling Wu; Stephen D Schmidt; Carl-Magnus Hogerkorp; Mark K Louder; Nancy S Longo; Christian Poulsen; Javier Guenaga; Bimal K Chakrabarti; Nicole Doria-Rose; Mario Roederer; Mark Connors; John R Mascola; Richard T Wyatt
Journal:  J Virol       Date:  2012-08-08       Impact factor: 5.103

4.  Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1.

Authors:  Xueling Wu; Zhi-Yong Yang; Yuxing Li; Carl-Magnus Hogerkorp; William R Schief; Michael S Seaman; Tongqing Zhou; Stephen D Schmidt; Lan Wu; Ling Xu; Nancy S Longo; Krisha McKee; Sijy O'Dell; Mark K Louder; Diane L Wycuff; Yu Feng; Martha Nason; Nicole Doria-Rose; Mark Connors; Peter D Kwong; Mario Roederer; Richard T Wyatt; Gary J Nabel; John R Mascola
Journal:  Science       Date:  2010-07-08       Impact factor: 47.728

5.  HIV-1 VACCINES. Priming a broadly neutralizing antibody response to HIV-1 using a germline-targeting immunogen.

Authors:  Joseph G Jardine; Takayuki Ota; Devin Sok; Matthias Pauthner; Daniel W Kulp; Oleksandr Kalyuzhniy; Patrick D Skog; Theresa C Thinnes; Deepika Bhullar; Bryan Briney; Sergey Menis; Meaghan Jones; Mike Kubitz; Skye Spencer; Yumiko Adachi; Dennis R Burton; William R Schief; David Nemazee
Journal:  Science       Date:  2015-06-18       Impact factor: 47.728

6.  Developmental pathway for potent V1V2-directed HIV-neutralizing antibodies.

Authors:  Nicole A Doria-Rose; Chaim A Schramm; Jason Gorman; Penny L Moore; Jinal N Bhiman; Brandon J DeKosky; Michael J Ernandes; Ivelin S Georgiev; Helen J Kim; Marie Pancera; Ryan P Staupe; Han R Altae-Tran; Robert T Bailer; Ema T Crooks; Albert Cupo; Aliaksandr Druz; Nigel J Garrett; Kam H Hoi; Rui Kong; Mark K Louder; Nancy S Longo; Krisha McKee; Molati Nonyane; Sijy O'Dell; Ryan S Roark; Rebecca S Rudicell; Stephen D Schmidt; Daniel J Sheward; Cinque Soto; Constantinos Kurt Wibmer; Yongping Yang; Zhenhai Zhang; James C Mullikin; James M Binley; Rogier W Sanders; Ian A Wilson; John P Moore; Andrew B Ward; George Georgiou; Carolyn Williamson; Salim S Abdool Karim; Lynn Morris; Peter D Kwong; Lawrence Shapiro; John R Mascola
Journal:  Nature       Date:  2014-03-02       Impact factor: 49.962

7.  Increasing the potency and breadth of an HIV antibody by using structure-based rational design.

Authors:  Ron Diskin; Johannes F Scheid; Paola M Marcovecchio; Anthony P West; Florian Klein; Han Gao; Priyanthi N P Gnanapragasam; Alexander Abadir; Michael S Seaman; Michel C Nussenzweig; Pamela J Bjorkman
Journal:  Science       Date:  2011-10-27       Impact factor: 47.728

8.  MolProbity: all-atom structure validation for macromolecular crystallography.

Authors:  Vincent B Chen; W Bryan Arendall; Jeffrey J Headd; Daniel A Keedy; Robert M Immormino; Gary J Kapral; Laura W Murray; Jane S Richardson; David C Richardson
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2009-12-21

9.  Restricting HIV-1 pathways for escape using rationally designed anti-HIV-1 antibodies.

Authors:  Ron Diskin; Florian Klein; Joshua A Horwitz; Ariel Halper-Stromberg; D Noah Sather; Paola M Marcovecchio; Terri Lee; Anthony P West; Han Gao; Michael S Seaman; Leonidas Stamatatos; Michel C Nussenzweig; Pamela J Bjorkman
Journal:  J Exp Med       Date:  2013-05-27       Impact factor: 14.307

10.  Phaser crystallographic software.

Authors:  Airlie J McCoy; Ralf W Grosse-Kunstleve; Paul D Adams; Martyn D Winn; Laurent C Storoni; Randy J Read
Journal:  J Appl Crystallogr       Date:  2007-07-13       Impact factor: 3.304

View more
  191 in total

1.  Immunological mechanisms of inducing HIV immunity in infants.

Authors:  Genevieve G Fouda; Kristina De Paris; Ofer Levy; Arnaud Marchant; Glenda Gray; Sallie Permar; Mary Marovich; Anjali Singh
Journal:  Vaccine       Date:  2019-11-21       Impact factor: 3.641

2.  Vaccination induces maturation in a mouse model of diverse unmutated VRC01-class precursors to HIV-neutralizing antibodies with >50% breadth.

Authors:  Xuejun Chen; Tongqing Zhou; Stephen D Schmidt; Hongying Duan; Cheng Cheng; Gwo-Yu Chuang; Ying Gu; Mark K Louder; Bob C Lin; Chen-Hsiang Shen; Zizhang Sheng; Michelle X Zheng; Nicole A Doria-Rose; M Gordon Joyce; Lawrence Shapiro; Ming Tian; Frederick W Alt; Peter D Kwong; John R Mascola
Journal:  Immunity       Date:  2021-01-15       Impact factor: 31.745

Review 3.  What Are the Primary Limitations in B-Cell Affinity Maturation, and How Much Affinity Maturation Can We Drive with Vaccination? Is Affinity Maturation a Self-Defeating Process for Eliciting Broad Protection?

Authors:  Christopher T Stamper; Patrick C Wilson
Journal:  Cold Spring Harb Perspect Biol       Date:  2018-05-01       Impact factor: 10.005

4.  Identification of Near-Pan-neutralizing Antibodies against HIV-1 by Deconvolution of Plasma Humoral Responses.

Authors:  Mohammad Mohseni Sajadi; Amir Dashti; Zahra Rikhtegaran Tehrani; William D Tolbert; Michael S Seaman; Xin Ouyang; Neelakshi Gohain; Marzena Pazgier; Dongkyoon Kim; Guy Cavet; Jean Yared; Robert R Redfield; George K Lewis; Anthony L DeVico
Journal:  Cell       Date:  2018-05-03       Impact factor: 41.582

5.  Immunogenetic and structural analysis of a class of HCV broadly neutralizing antibodies and their precursors.

Authors:  Fernando Aleman; Netanel Tzarum; Leopold Kong; Kenna Nagy; Jiang Zhu; Ian A Wilson; Mansun Law
Journal:  Proc Natl Acad Sci U S A       Date:  2018-06-28       Impact factor: 11.205

Review 6.  Advancing an HIV vaccine; advancing vaccinology.

Authors:  Dennis R Burton
Journal:  Nat Rev Immunol       Date:  2019-02       Impact factor: 53.106

7.  Conformational Engineering of HIV-1 Env Based on Mutational Tolerance in the CD4 and PG16 Bound States.

Authors:  Jeremiah D Heredia; Jihye Park; Hannah Choi; Kevin S Gill; Erik Procko
Journal:  J Virol       Date:  2019-05-15       Impact factor: 5.103

8.  Effects of partially dismantling the CD4 binding site glycan fence of HIV-1 Envelope glycoprotein trimers on neutralizing antibody induction.

Authors:  Ema T Crooks; Keiko Osawa; Tommy Tong; Samantha L Grimley; Yang D Dai; Robert G Whalen; Daniel W Kulp; Sergey Menis; William R Schief; James M Binley
Journal:  Virology       Date:  2017-03-06       Impact factor: 3.616

Review 9.  Progress in HIV vaccine development.

Authors:  Denise C Hsu; Robert J O'Connell
Journal:  Hum Vaccin Immunother       Date:  2017-03-10       Impact factor: 3.452

10.  Glycan Masking Focuses Immune Responses to the HIV-1 CD4-Binding Site and Enhances Elicitation of VRC01-Class Precursor Antibodies.

Authors:  Hongying Duan; Xuejun Chen; Jeffrey C Boyington; Cheng Cheng; Yi Zhang; Alexander J Jafari; Tyler Stephens; Yaroslav Tsybovsky; Oleksandr Kalyuzhniy; Peng Zhao; Sergey Menis; Martha C Nason; Erica Normandin; Maryam Mukhamedova; Brandon J DeKosky; Lance Wells; William R Schief; Ming Tian; Frederick W Alt; Peter D Kwong; John R Mascola
Journal:  Immunity       Date:  2018-07-31       Impact factor: 31.745

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.